Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
Graves’ ophthalmopathy, also called Graves’ orbitopathy, is a potentially sight-threatening ocular disease that has puzzled physicians and scientists for nearly two centuries. Generally occurring in patients with hyperthyroidism or a history of hyperthyroidism due to Graves’ disease, Graves’ ophthalmopathy is also known as thyroid-associated ophthalmopathy or thyroid eye disease, because it sometimes occurs in patients with euthyroid or hypothyroid chronic autoimmune thyroiditis. The condition has an annual adjusted incidence rate of 16 women and 3 men per 100,000 population. This review explores the perplexing relationship between Graves’ ophthalmopathy, hyperthyroidism, and thyroid dermopathy, the associated skin condition. I examine clinical features, histologic findings, and laboratory studies, with an emphasis on mechanisms that could be targeted in the development of new treatments for this debilitating disease.
格雷夫斯眼病,也称为格雷夫斯眼病,是一种潜在的致盲性眼病,近两个世纪以来一直困扰着医生和科学家。格雷夫斯眼病通常发生在甲状腺功能亢进症患者或因格雷夫斯病导致甲状腺功能亢进症病史的患者中,也称为甲状腺相关眼病或甲状腺眼病,因为它有时发生在甲状腺功能正常或甲状腺功能减退的慢性自身免疫性甲状腺炎患者中。这种情况的年调整发病率为每 10 万人中有 16 名女性和 3 名男性。本综述探讨了格雷夫斯眼病、甲状腺功能亢进症和甲状腺皮病(相关皮肤疾病)之间令人费解的关系。我检查了临床特征、组织学发现和实验室研究,重点关注可能成为治疗这种使人衰弱疾病新疗法靶点的机制。